Centre Hospitalier Universitaire De Bordeaux

The Oncology program at Centre Hospitalier Universitaire De Bordeaux includes a strong focus on neoplasms, especially melanoma, renal cell carcinoma, and head and neck cancers. These studies are designed to evaluate new immunotherapy approaches, improve recurrence prevention, and compare treatment effectiveness in advanced or resected disease.

• Advanced and metastatic melanoma, including recurrence prevention after surgery
• Renal cell carcinoma and other advanced solid tumors
• Head and neck squamous cell carcinoma and related malignancies

This research reflects a broad effort to test innovative cancer therapies and improve outcomes for patients with difficult-to-treat tumors.

A substantial part of the site’s clinical research addresses skin and connective tissue diseases and immune system diseases, including atopic dermatitis, hidradenitis suppurativa, prurigo nodularis, and alopecia areata. The trials aim to assess symptom control, long-term disease management, and the effectiveness of new or established treatments.

• Atopic dermatitis in adolescents and adults
• Hidradenitis suppurativa and prurigo nodularis
• Alopecia areata and vitiligo

These studies are centered on improving quality of life by testing therapies that may better control chronic inflammatory skin conditions.

The site also conducts studies in virus diseases and broader immune system diseases, including HIV and vaccine-response research. At Centre Hospitalier Universitaire De Bordeaux, this work explores how well preventive or immune-based strategies perform in people living with chronic viral infection and related health conditions.

• HIV-1 infection and long-term treatment follow-up
• Recombinant zoster vaccine immune response in older adults living with HIV
• Supportive immunology studies in people with chronic infection

The goal is to better understand immune protection and strengthen preventive care in populations with ongoing viral health needs.

Research here extends beyond cancer into immune system diseases, eye diseases, and other chronic inflammatory conditions such as giant cell arteritis, Sjögren’s syndrome, and non-infectious uveitis. These trials are focused on evaluating treatment effectiveness, maintaining remission, and reducing disease activity over time.

• Giant cell arteritis and treatment discontinuation strategies
• Sjögren’s syndrome and inflammatory control
• Uveitis and related eye disease management

This work supports more personalized care for patients with autoimmune and inflammatory disorders that can affect vision, comfort, and daily function.

The clinical trial portfolio also includes digestive system diseases and male urogenital diseases, with studies in hepatocellular carcinoma, germ-cell tumors, and other advanced malignancies. These trials are intended to test new combinations, refine treatment strategies, and improve survival in aggressive cancers.

• Unresectable hepatocellular carcinoma
• Non-seminomatous germ-cell tumors
• Other advanced or metastatic solid tumors

The research reflects a commitment to expanding options for patients facing complex cancers with limited standard treatments.